Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on May 1, 2023, to announce its first-quarter 2023 financial results. This filing primarily incorporates by reference a press release issued on the same date, which details the company's performance for the three months ended March 31, 2023. Investors should refer to the attached press release (Exhibit 99.1) for specific financial figures, operational updates, and forward-looking statements. The press release is the primary source of information regarding Vertex's financial condition and results of operations for the period. While the 8-K itself is brief, it serves as the formal notification of the release of this important financial data. The company emphasizes that the information in the press release is furnished, not filed, and thus not subject to specific liabilities under certain sections of the Securities Exchange Act of 1934, though it is incorporated by reference into this filing.
Key Highlights
- 1Vertex Pharmaceuticals filed an 8-K on May 1, 2023, to report Q1 2023 financial results.
- 2The 8-K filing incorporates by reference a press release dated May 1, 2023 (Exhibit 99.1) containing detailed financial results for the three months ended March 31, 2023.
- 3Investors should consult the attached press release for specific performance metrics and financial details.
- 4The company is formally notifying the SEC of its Q1 2023 financial results release.
- 5Information furnished in the press release is not deemed 'filed' for certain legal purposes under the Securities Exchange Act of 1934.